Gemphire Therapeutics

Nasdaq

Biotech

NeuroBo backs onto Nasdaq via merger with Gemphire

The move comes as NeuroBo gears up to start a phase 3 trial of nerve growth factor therapy NB-01 in patients with diabetic neuropathic pain.

Nick Paul Taylor Jul 26, 2019 9:03am

Parachute

Curis moves up COO as CEO Fattaey departs—Chutes & Ladders

Sep 28, 2018 10:00am

Axe and chopping block

Gemphire cuts 33% of staff, including CFO, CMO

Sep 25, 2018 10:10am

Image subject to copyright

Gemphire pulls the plug on fatty liver disease trial

Aug 10, 2018 10:30am